Clinical trial
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
NCT00709618
Study timeline
Study start (unknown)2008-06-01Date precision: month
Registry last updated2014-07-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Neoplasms, Breastunresolved
Interventions
Sponsors & collaborators
GlaxoSmithKlinelead sponsor
Mapped research locations
New YorkNew York, United States1PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1ColumbusOhio, United States1PortlandOregon, United States1JacksonvilleFlorida, United States1Oklahoma CityOklahoma, United States1OmahaNebraska, United States1TucsonArizona, United States1BethesdaMaryland, United States1SacramentoCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00709618 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.